Atossa Genetics (NASDAQ:ATOS) Shares Pass Below Two Hundred Day Moving Average – Time to Sell?

Shares of Atossa Genetics Inc. (NASDAQ:ATOS) crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $7.14 and traded as low as $4.65. Atossa Genetics shares last traded at $4.85, with a volume of 46,768 shares trading hands.

Wall Street Analysts Forecast Growth

ATOS has been the subject of a number of recent research reports. Weiss Ratings upgraded shares of Atossa Genetics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 22nd. Ascendiant Capital Markets decreased their price target on shares of Atossa Genetics from $120.00 to $24.00 and set a “buy” rating for the company in a research note on Friday, April 10th. Finally, HC Wainwright boosted their price target on shares of Atossa Genetics to $25.00 and gave the company a “buy” rating in a research note on Thursday, March 26th. Two investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $24.50.

Atossa Genetics Trading Down 7.8%

The stock has a market capitalization of $38.49 million, a PE ratio of -1.39 and a beta of 1.24. The stock’s fifty day simple moving average is $5.22 and its 200-day simple moving average is $7.12.

Atossa Genetics (NASDAQ:ATOS) last posted its quarterly earnings data on Friday, May 8th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.12). As a group, analysts anticipate that Atossa Genetics Inc. will post -4.41 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Atossa Genetics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. XTX Topco Ltd boosted its holdings in shares of Atossa Genetics by 581.2% in the 4th quarter. XTX Topco Ltd now owns 169,261 shares of the company’s stock worth $100,000 after buying an additional 144,412 shares during the last quarter. &PARTNERS bought a new stake in shares of Atossa Genetics during the fourth quarter valued at about $25,000. Graham Capital Management L.P. increased its position in shares of Atossa Genetics by 27.8% during the fourth quarter. Graham Capital Management L.P. now owns 211,369 shares of the company’s stock valued at $125,000 after buying an additional 45,923 shares during the period. State Street Corp increased its position in shares of Atossa Genetics by 31.2% in the fourth quarter. State Street Corp now owns 596,485 shares of the company’s stock worth $352,000 after purchasing an additional 141,990 shares during the last quarter. Finally, Renaissance Technologies LLC increased its position in shares of Atossa Genetics by 33.2% in the fourth quarter. Renaissance Technologies LLC now owns 2,062,838 shares of the company’s stock worth $1,217,000 after purchasing an additional 514,175 shares during the last quarter. 12.74% of the stock is owned by hedge funds and other institutional investors.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.